Latest News - BioPharmX Corporation

Thursday, April 20, 2017 | PracticalDermatology.com, Product Launches and Updates, BioPharmX Corporation

BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soon

BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now pl…

Read the full story

Monday, January 23, 2017 | Personnel/Company News, PracticalDermatology.com, BioPharmX Corporation, BioPharmX Corporation

Specialty Pharma Industry Vet Charles Gregory Vontz Joins BioPharmX Board of Directors

Charles "Greg" Vontz  is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17.  Vontz's appointment expands the board …

Read the full story

Wednesday, January 04, 2017 | PracticalDermatology.com, Product Launches and Updates, Research and Publications, BioPharmX Corporation, BioPharmX Corporation

Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acne

BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vul…

Read the full story

Thursday, November 10, 2016 | PracticalDermatology.com, Research and Publications, BioPharmX Corporation

Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantages

Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne …

Read the full story